FDA staff said the move to allow compounding of some unapproved peptide products raises patient safety concerns and weakens ...
Medical Microinstruments raised $125m in Series D funding, led by BioStar Capital. The firm will use the funds to expand ...
Results from a comparison of mifepristone's safety to surgical abortion are expected in December with a final report in March ...
Stay ahead of every shift in generics and biosimilars. Generics Bulletin brings you the latest updates that matter for the off-patent industry.
Edwards and Highlife’s mitral valve replacement systems will receive health technology assessment (HTA) at an EU level via a ...
Leaders in the cell therapy field talked about how to expand access to CAR-T cell therapy, with one exec saying bringing it ...
The German group is hoping to get the green light for the mineralocorticoid receptor antagonist for adults with chronic ...
Former US FDA advisory committee chair Eric Brass told the AESGP switch conference in Brussels that switch decisions focus ...
Stay ahead of every shift in generics and biosimilars. Generics Bulletin brings you the latest updates that matter for the off-patent industry.
Analysts see a role for the amylin agonist thanks to placebo-like tolerability, but Lilly and Novo candidates in the class ...
The successor to Emer Cooke as head of the European Medicines Agency could be identified soon, with the successful candidate ...
Arrowhead's severe hypertriglyceridemia (sHTG) filing for Redemplo is the first known entry into the FDA's STAR pilot, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results